Transcriptomics

Dataset Information

0

Development of a LRRC15-Targeted Radio-immunotheranostic Approach to Deplete Pro-tumorigenic Mechanisms and Immunotherapy Resistance


ABSTRACT: Leucine-rich repeat containing 15 (LRRC15) has emerged as an attractive biomarker and target for cancer therapy. We have developed a humanized monoclonal antibody (mAb), DUNP19, that specifically binds to a phylogenetically conserved LRRC15 epitope and is internalized by target-expressing cancer and stromal cells. In xenograft mouse models, Lutetium-177 labeled DUNP19 ([177Lu]-DUNP19) enables non-invasive imaging and precise radiotherapy to LRRC15-expressing cancer cells and murine cancer-associated fibroblasts (CAFs), halting tumor progression and prolonging survival with minimal toxicity. Transcriptomic analyses of [177Lu]-DUNP19-treated tumors reveal a loss of pro-tumorigenic mechanisms, including a transforming growth factor beta (TGFβ)-driven and LRRC15+ signature associated with immunotherapy resistance. Together, these results demonstrate that radio-theranostic targeting of LRRC15 with DUNP19 is a compelling precision medicine platform for image-guided diagnosis, eradication, and reprogramming of LRRC15+ tumor tissue that drives immuno-resistance and aggressive disease.

ORGANISM(S): Homo sapiens

PROVIDER: GSE260644 | GEO | 2025/06/02

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2022-09-07 | PXD036034 | Pride
| PRJNA1082393 | ENA
| 2743256 | ecrin-mdr-crc
2018-10-27 | GSE106280 | GEO
2021-09-01 | GSE175486 | GEO
2018-10-27 | GSE106283 | GEO
2017-03-08 | GSE80022 | GEO
2025-06-02 | PXD055521 | Pride
2022-08-16 | E-MTAB-12028 | biostudies-arrayexpress
2024-04-01 | GSE200619 | GEO